Transcatheter Mitral-Valve Repair in Patients with Heart Failure
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients with heart failure who have mitral regurgitation due to left ventricular dysfunction, the prognosis is poor. Transcatheter mitral-valve repair may improve their clinical outcomes. METHODS: At 78 sites in the United States and Canada, we enrolled patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remained symptomatic despite the use of maximal doses of guideline-directed medical therapy. Patients were randomly assigned to transcatheter mitral-valve repair plus medical therapy (device group) or medical therapy alone (control group). The primary effectiveness end point was all hospitalizations for heart failure within 24 months of follow-up. The primary safety end point was freedom from device-related complications at 12 months; the rate for this end point was compared with a prespecified objective performance goal of 88.0%. RESULTS: Of the 614 patients who were enrolled in the trial, 302 were assigned to the device group and 312 to the control group. The annualized rate of all hospitalizations for heart failure within 24 months was 35.8% per patient-year in the device group as compared with 67.9% per patient-year in the control group (hazard ratio, 0.53; 95% confidence interval [CI], 0.40 to 0.70; P<0.001). The rate of freedom from device-related complications at 12 months was 96.6% (lower 95% confidence limit, 94.8%; P<0.001 for comparison with the performance goal). Death from any cause within 24 months occurred in 29.1% of the patients in the device group as compared with 46.1% in the control group (hazard ratio, 0.62; 95% CI, 0.46 to 0.82; P<0.001). CONCLUSIONS: Among patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remained symptomatic despite the use of maximal doses of guideline-directed medical therapy, transcatheter mitral-valve repair resulted in a lower rate of hospitalization for heart failure and lower all-cause mortality within 24 months of follow-up than medical therapy alone. The rate of freedom from device-related complications exceeded a prespecified safety threshold. (Funded by Abbott; COAPT ClinicalTrials.gov number, NCT01626079 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The magnitude of the tirzepatide-mediated improvement in the win ratio was large and similar to the effect of transcatheter mitral valve repair in patients with HF and secondary mitral regurgitation.32”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [32]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2017 ESC/EACTS Guidelines for the management of valvular heart disease
Baumgartner, H., Falk, V., Bax, J. J., De Bonis, M., Hamm, C., Holm, P. J., Iung, B., Lancellotti, P., Lansac, E., Rodriguez Muñoz, D., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx391 · Cited by 6,243
Zoghbi, W. A., Enriquez-Sarano, M., Foster, E., Grayburn, P. A., Kraft, C. D., Levine, R. A., Nihoyannopoulos, P., Otto, C. M., Quinones, M. A., Rakowski, H., et al. (2003) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(03)00335-3 · Cited by 4,044
Self-citation2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Self-citationNishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Fleisher, L. A., Jneid, H., Mack, M. J., McLeod, C. J., O’Gara, P. T., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.011 · Cited by 3,339
Self-citationPercutaneous Repair or Surgery for Mitral Regurgitation
Feldman, T., Foster, E., Glower, D. D., Kar, S., Rinaldi, M. J., Fail, P. S., Smalling, R. W., Siegel, R., Rose, G. A., Engeron, E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009355 · Cited by 2,183
Self-citationThe prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation
Goldstein, D., Moskowitz, A. J., Gelijns, A. C., Ailawadi, G., Parides, M. K., Perrault, L. P., Hung, J. W., Voisine, P., Dagenais, F., Gillinov, A. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512913 · Cited by 972
Self-citationPercutaneous Mitral Valve Interventions in the Real World
Maisano, F., Franzen, O., Baldus, S., Schäfer, U., Hausleiter, J., Butter, C., Ussia, G. P., Sievert, H., Richardt, G., Widder, J. D., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.094 · Cited by 839
Stone, G. W., Adams, D. H., Abraham, W. T., Kappetein, A. P., Généreux, P., Vranckx, P., Mehran, R., Kuck, K.-H., Leon, M. B., Piazza, N., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.049 · Cited by 594
Self-citationSecondary Mitral Regurgitation in Heart Failure
Asgar, A. W., Mack, M. J., & Stone, G. W. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.009 · Cited by 489
Self-citation
Research works printed but not linked: 1
- 16. cancer events. Biostatistics 2007; 8: 70821.
Cited by
Items 601–700 of 1,001
Update on heart failure management and future directions
Choi, H., Park, M., & Youn, J. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.428.e1 · Cited by 20
Cardio-Hepatic Syndrome in Patients Undergoing Mitral Valve Transcatheter Edge-to-Edge Repair
Stolz, L., Orban, M. W., Karam, N., Lubos, E., Wild, M. G., Weckbach, L. T., Stocker, T. J., Praz, F., Braun, D., Löw, K., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2842 · Cited by 20
The year in cardiology: valvular heart disease
Binder, R. K., Dweck, M. R., & Prendergast, B. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz948 · Cited by 20
Elbadawi, A., Elgendy, I. Y., Mohamed, A. H., Almahmoud, M. F., Omer, M. A., Abuzaid, A., Mahmoud, K., Ogunbayo, G. O., Denktas, A. E., Paniagua, D. E., et al. (2020) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2020.05.021 · Cited by 20
A New Age for Transcatheter Mitral Valve Repair
Praz, F., Winkel, M., & Fam, N. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.07.023 · Cited by 20
Transcatheter mitral repair and replacement: which procedure for which patient?
Taramasso, M., Gavazzoni, M., Nickenig, G., & Maisano, F. (2019) · EuroIntervention · doi:10.4244/eij-d-19-00743 · Cited by 19
Bias and Loss to Follow‐Up in Cardiovascular Randomized Trials: A Systematic Review
Fong, L. C. W., Ford, T. J., da Costa, B. R., Jüni, P., & Berry, C. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015361 · Cited by 19
Iriart, X., Guérin, P., Jalal, Z., & Thambo, J. (2021) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29681 · Cited by 19
The Role of Cardiac Resynchronization Therapy for the Management of Functional Mitral Regurgitation
Russo, E., Russo, G., Cassese, M., Braccio, M., Carella, M., Compagnucci, P., Russo, A. D., & Casella, M. (2022) · Cells · doi:10.3390/cells11152407 · Cited by 19
Freixa, X., y, A. J.-R., Cid, B., & Cruz‐González, I. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2022.08.008 · Cited by 19
Caneiro-Queija, B., Raposeiras-Roubín, S., Adamo, M., Freixa, X., Arzamendi, D., Benito-González, T., Montefusco, A., Pascual, I., Nombela-Franco, L., Rodés-Cabau, J., et al. (2022) · Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease · doi:10.1161/jaha.121.023121 · Cited by 13
Quantification of primary mitral regurgitation by echocardiography: A practical appraisal
Altes, A., Vermès, E., Lévy, F., Vancraeynest, D., Pasquet, A., Vincentelli, A., Gerber, B. L., Tribouilloy, C. M., & Maréchaux, S. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1107724 · Cited by 19
“This is notably due to the intense debate surrounding the discrepant results between the COAPT and MITRA-FR trials which assessed the efficacy of transcatheter edge-to-edge repair for secondary MR (135, 136).”
ResultImpact of Percutaneous Mitral Valve Repair on Left Atrial Strain and Atrial Fibrillation Progression
Romano, L. R., Scalzi, G., Malizia, B., Aquila, I., Polimeni, A., Indolfi, C., & Curcio, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080320 · Cited by 19
“The main inclusion criteria, according to the COAPT trial [14], were symptomatic HF in New York Heart Association (NYHA) functional class II, III or ambulatory IV; LV ejection fraction (LVEF) > 20%; LV diameter ≤ 70 mm; anatomy judged suitable for TEER.”
MethodHamada, S., Ueyama, H. A., Aikawa, T., Kampaktsis, P. Ν., Misumida, N., Takagi, H., Kuno, T., & Latib, A. (2023) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.30806 · Cited by 19
“The COAPT trial displayed reductions in heart failure hospitalizations and all‐ cause mortality with TEER compared to medical therapy alone, whereas MITRA‐FR showed no clinical benefits of TEER.(10,11) This was attributed to patients in the COAPT trial having a greater severity of MR in relation to smaller LV dimensio…”
ResultFutile MITRA-FR and a positive COAPT trial: Where does the evidence leave the clinicians?
Arora, G., Patel, N., & Arora, P. K. (2018) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2018.11.003 · Cited by 19
Packer, M. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1469 · Cited by 19
Khalique, O. K., & Hahn, R. T. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00142 · Cited by 19
“FDA approval for use of the edge-to-edge repair device for functional MR was based on the results of the Cardiovascular Outcomes Assessment of the Mitraclip Percutaneous Therapy for Heart Failure PatientsWith Functional Mitral Regurgitation (COAPT) trial (7).”
MethodEchocardiography update for primary care physicians: a review
Chan, J. S. K., Tse, G., Zhao, H., Xx, L., Jin, C., Kam, K. K., Fan, Y. K., & Lee, A. P. (2020) · Hong Kong Medical Journal · doi:10.12809/hkmj198080 · Cited by 19
Debonnaire, P., Heyning, C. M. V. D., Haddad, M. E., Coussement, P. K., Paelinck, B. P., CEUNINCK, M. D., Timmermans, F., Bock, D. D., Drieghe, B., Dujardin, K., et al. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.03.045 · Cited by 19
Mitral and Tricuspid Transcatheter Interventions Current Indications and Future Directions
Winkel, M., Praz, F., & Wenaweser, P. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00061 · Cited by 19
“Procedural success was high (98%), durable throughout 2 years (95%), and the procedure was safe (no peri-procedural complications in 97% of patients) (11).”
BackgroundIzumo, M., Kuwata, S., Ishibashi, Y., Suzuki, T., Ohara, H., Watanabe, M., Sato, Y., Nishikawa, H., Okuyama, K., Kamijima, R., et al. (2020) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaa200 · Cited by 19
Kreußer, M. M., Hamed, S., Weber, A., Schmack, B., Volz, M. J., Geis, N. A., Großekettler, L., Pleger, S. T., Ruhparwar, A., Katus, H. A., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12982 · Cited by 19
“Mean PA pressure (mmHg) 35 [31; 40] 35 [30; 42] 0.”
Shore, J., Russell, J. P., Frankenstein, L., Candolfi, P., & Green, M. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1854769 · Cited by 19
Extrusion of impacted teeth using mini-implant mechanics.
Nienkemper, M., Wilmes, B., Lübberink, G., Ludwig, B., & Drescher, D. (2012) · PubMed · Cited by 19
Pausch, J., Gross, T. S., Müller, L., von Stumm, M., Kloth, B., Reichenspurner, H. C., & Girdauskas, E. (2021) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezab048 · Cited by 19
Pulmonary Hypertension in Heart Failure
Jang, A. Y., Park, S. J., & Chung, W. (2021) · International Journal of Heart Failure · doi:10.36628/ijhf.2020.0053 · Cited by 19
Anker, S. D., Starling, R. C., Khan, M. S., Friede, T., Filippatos, G. S., Lindenfeld, J., von Bardeleben, R. S., Coats, A. J. S., & Butler, J. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.03.002 · Cited by 19
Self-citationSilini, A., & Iriart, X. (2022) · International Journal of Cardiology Congenital Heart Disease · doi:10.1016/j.ijcchd.2022.100370 · Cited by 19
Iliadis, C., Kalbacher, D., Lurz, P. C., Petrescu, A. M., Orban, M., Puscas, T., Lupi, L., Stazzoni, L., Pires‐Morais, G., Koell, B., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2565 · Cited by 19
Myocardial fibrosis predicts adverse outcome after MitraClip implantation
Velu, J. F., Hirsch, A., Boekholdt, S. M., Koch, K. T., Vis, M. M., Planken, R. N., Piek, J. J., Baan, J., & Bouma, B. J. (2018) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.27993 · Cited by 19
Impact of mitral valve treatment choice on mortality according to aetiology
Kortlandt, F., Velu, J. F., Schurer, R. A. J., den Branden, B. V., Bouma, B. J., Kelder, J. C., Eefting, F. D., Swaans, M. J., Rensing, B. J. W. M., Baan, J., et al. (2019) · EuroIntervention · doi:10.4244/eij-d-18-00874 · Cited by 19
Pulmonary Hypertension Due to Left Heart Disease: an Update
Aras, M. A., Psotka, M. A., & Marco, T. D. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1149-1 · Cited by 19
Baldus, S. E., von Bardeleben, R. S., Eggebrecht, H., Elsässer, A., Hausleiter, J., İnce, H., Kelm, M., Kück, K., Lubos, E., NEF, H. M., et al. (2020) · Der Kardiologe · doi:10.1007/s12181-020-00409-w · Cited by 19
Pascual, I., Arzamendi, D., Carrasco‐Chinchilla, F., Fernández‐Vázquez, F., Freixa, X., y, L. N.-F., y, P. A., Serrador, A., Pan, M., Álvarez, A. B. C., et al. (2019) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2019.07.018 · Cited by 18
“13,14 Thus, the main objective of this study was to analyze the differences in 1-year all-cause mortality and hospital readmissions for HF in patients with degenerative, functional, and mixed MR managed with TMVR with the MitraClip system.”
BackgroundImpact of Mitral Annular Dilation on Edge-to-Edge Therapy With MitraClip-XTR
Kreidel, F., Zaid, S., Tamm, A., Ruf, T. F., Beiras-Fernández, A., Reinold, J., Geyer, M., Silva, J. G. D. R. E., Schnitzler, K., Hell, M. M., et al. (2021) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.120.010447 · Cited by 18
Fan, Y., Chan, J. S. K., & Lee, A. P. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.864341 · Cited by 18
“There are several advantages for using live 3D MPR in the guidance of the TEER procedure: (1) the errors of parallax (perceived shift in position of a structure when it is viewed from different angles on 3D echocardiography) can be minimized by simultaneously displaying the 2D views and 3D images; (2) 2D views that ar…”
MethodAkansel, S., Kofler, M., Praet, K. M. V., Unbehaun, A., Sündermann, S., Jacobs, S., Falk, V., & Kempfert, J. (2022) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivac163 · Cited by 18
Burgess, S. N., Cader, F. A., Shaw, E. A., Banerjee, S., Stehli, J., Krishnamorthy, R., Khor, L., Forotan, H., Bastiany, A., Rao, S., et al. (2022) · European Cardiology Review · doi:10.15420/ecr.2022.33 · Cited by 18
“PARTNER I trial13 2011 0/23 (0) 1/23 (4) 0/2 (0) 330/699 (43) 84”
Safarkhanlo, Y., Jung, B. A., Bernhard, B., Peper, E. S., Kwong, R. Y. K., Bastiaansen, J., & Gräni, C. (2023) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-023-02893-z · Cited by 18
“Conflicting data from large randomized clinical trials on the value of transcatheter mitral valve edge-to-edge repair [39, 40] underline the urgent need for a reproducible and robust quantification of MVR severity that correlates with outcomes and can be used to guide therapeutic decisions [41].”
BackgroundMitral Valve Interventions for Hypertrophic Obstructive Cardiomyopathy
Shuvy, M., Postell, Y. Y., Carasso, S., Marmor, D. B., Strauss, B. H., Maisano, F., & Lapenna, E. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.12.009 · Cited by 18
Grayburn, P. A., Mack, M. J., Manandhar, P., Kosinski, A. S., Sannino, A., Smith, R. L., Szerlip, M., & Vemulapalli, S. (2024) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.123.013581 · Cited by 18
Self-citationMortality Burden for Patients With Untreated Aortic Regurgitation
Généreux, P., Amoroso, N. S., Thourani, V. H., Rodríguez, E., Sharma, R. P., Pinto, D. S., Kwon, M., Dobbles, M., Pellikka, P. A., & Gillam, L. D. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101228 · Cited by 18
Potter, B. M., Orton, E. C., Scansen, B. A., Abbott-Johnson, K. M., Visser, L. C., Chi, I.-J. B., Ross, E. S., Nero, B. D., Tantisuwat, L., Krause, E. T., et al. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1448828 · Cited by 18
Patterson, T., Adams, H. S. L., Allen, C. J., Rajani, R., Prendergast, B., & Redwood, S. R. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00060 · Cited by 18
“Recent randomized trial data in favor of edge-to-edge repair in FMR would suggest a greater benefit in patients with severe heart failure symptoms (NYHA III-IV), larger regurgitant volume, with smaller LV end-diastolic dimensions (23, 28).”
BackgroundSeese, L., Sultan, I. S., Gleason, T. G., Wang, Y., Thoma, F. W., Navid, F., & Kilic, A. (2019) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2019.08.033 · Cited by 18
Haußig, S., Linke, A. H.-P., & Mangner, N. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01335-9 · Cited by 18
Nappi, F., Nenna, A., Mihos, C. G., Spadaccio, C., Gentile, F., Chello, M., & Matzui, Y. (2021) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-020-01562-5 · Cited by 18
Kagiyama, N., Toki, M., Yuri, T., Aritaka, S., Hayashida, A., Sengupta, P. P., & Yoshida, K. (2021) · Open Heart · doi:10.1136/openhrt-2021-001583 · Cited by 18
“6 The dynamic nature of the severity of MR is one of the major difficulties encountered in evaluation of secondary MR. 9 Exercise stress echocardiography (ESE) for evaluation of valvular heart disease is a well-known examination, which allows real-time evaluation of the dynamic changes in the…”
Arnold, S. V., Stone, G. W., Jain, S. S., Mack, M. J., Saxon, J. T., Zhang, Z., Lindenfeld, J. M., Abraham, W. T., & Cohen, D. J. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.04.012 · Cited by 18
Self-citationNew Perspective on Pathophysiology and Management of Functional Mitral Regurgitation
Kumar, M., Thompson, P. D., & Chen, K. (2022) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2022.03.001 · Cited by 18
Oßwald, A., Shehada, S.-E., Zubarevich, A., Kamler, M., Thielmann, M., Sommer, W., Weymann, A., Ruhparwar, A., Gabry, M. E., & Schmack, B. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1229336 · Cited by 18
“Treatment of MR and advanced heart failure remains challenging, but studies have shown superiority of interventional treatment compared to medical treatment alone (11, 12).”
ResultEchocardiographic guidance for transcatheter mitral valve repair using edge-to-edge clip
Aman, E. A., & Smith, T. W. (2019) · Journal of Echocardiography · doi:10.1007/s12574-019-00417-0 · Cited by 18
Impact of transcatheter mitral valve repair on ventricular arrhythmias
Ledwoch, J., Nommensen, A., Keelani, A., Meyer‐Saraei, R., Stiermaier, T., Saad, M. F., Pöss, J., Desch, S., Tilz, R. R., Thiele, H., et al. (2019) · EP Europace · doi:10.1093/europace/euz061 · Cited by 18
Gallo, G., Forte, M., Stanzione, R., Cotugno, M., Bianchi, F., Marchitti, S., Berni, A., Volpe, M., & Rubattu, S. D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051348 · Cited by 18
Kang, J. J. H., Bozso, S. J., EL‐Andari, R., Adams, C. A., & Nagendran, J. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000803 · Cited by 18
“The COAPT trial published in 2018 [5] was the first study to suggest that interventions with MitraClip (Abbott, Abbott Park, IL, USA), which uses the edge-to-edge repair technique developed by Alfieri [6], improves all-cause mortality in selected patients with functional mitral regurgitation when compared to guideline…”
MethodLiu, X., Pu, Z., Lim, D. S., & Wang, J. (2021) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29687 · Cited by 18
Self-citationMirizzi, A. M., Crimi, G., Raineri, C., Magrini, G., Gazzoli, F., Frassica, R., Gritti, V., Montalto, C., Scelsi, L., Turco, A., et al. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13676 · Cited by 18
Imaging in Structural Heart Disease
Faza, N. N., Tok, Ö. Ö., & Hahn, R. T. (2019) · JACC Case Reports · doi:10.1016/j.jaccas.2019.08.012 · Cited by 18
“In the mitral space, the MitraClip (Abbott Structural, Minneapolis, Minnesota) device, studied under the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial, has shown decreased re-hospitalizations and mortality in medic…”
MethodA Volume-Based Framework Reconciling COAPT, MITRA-FR, and RESHAPE-HF2
Gupta, A., Packer, M., Makkar, R., & Grayburn, P. A. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.029 · Cited by 18
Self-citationTranscatheter Aortic-Valve Replacement in Low-Risk Patients
Baldetti, L., Beneduce, A., & Gallone, G. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1908500 · Cited by 17
Self-citationBanga, S., Hafiz, A. M., Chami, Y. G., Gumm, D. C., Banga, P., Howard, C., Kim, M. C., & Sengupta, P. P. (2020) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaa019 · Cited by 17
“mean (SD) 10 (6) 11 (6) NA NA NA NA 6 (3) 10 (4) NA NA”
Stolz, L., Braun, D., Higuchi, S., Orban, M., Doldi, P. M., Stocker, T. J., Weckbach, L. T., Wild, M. G., Hagl, C. M., Maßberg, S., et al. (2022) · Expert Review of Medical Devices · doi:10.1080/17434440.2022.2098013 · Cited by 17
Freixa, X., y, A. J.-R., Cid, B., & Cruz‐González, I. (2022) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2022.10.002 · Cited by 17
Wang, T. K. M., Koçyiğit, D., Choi, H., Anthony, C. M., Chan, N., Bullen, J. A., Popović, Z., Kapadia, S. R., Krishnaswamy, A., Griffin, B. P., et al. (2023) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.122.015134 · Cited by 17
Self-citationManagement of secondary mitral regurgitation: from drugs to devices
Barnes, C., Sharma, H. C., Gamble, J. H. P., & Dawkins, S. (2023) · Heart · doi:10.1136/heartjnl-2022-322001 · Cited by 17
Simonian, N. T., Liu, H., Vakamudi, S., Pirwitz, M. J., Pouch, A. M., Gorman, J. H., Gorman, R. C., & Sacks, M. S. (2023) · Cardiovascular Engineering and Technology · doi:10.1007/s13239-023-00680-4 · Cited by 17
“The recent MITRA-FR and COAPT studies compared treatment with MitraClip plus GDMT versus GDMT alone in seemingly similar cohorts of patients with severe FMR [32, 33].”
ResultTranscatheter edge-to-edge repair for mitral regurgitation
von Stein, P., & Iliadis, C. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.02.004 · Cited by 17
Management of Structural Heart Disease and Acute Coronary Syndromes in the COVID-19 Pandemic
Giordano, A., Biondi‐Zoccai, G., Frati, G., & Bartorelli, A. L. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00849-5 · Cited by 17
“Analogous evidence in favor of transcatheter repair of functional mitral regurgitation has been reported by the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) trial [8].”
ResultWorthley, S. G., Redwood, S. R., Hildick‐Smith, D., Rafter, T., Whelan, A. P., MARCO, F. D., Horrigan, M., Delacroix, S., Gregson, J., & Ērglis, A. (2021) · EuroIntervention · doi:10.4244/eij-d-20-00484 · Cited by 17
Predictors of outcomes in patients with mitral regurgitation undergoing percutaneous valve repair
Polimeni, A., Albanese, M., Salerno, N., Aquila, I., Sabatino, J., Sorrentino, S., Leo, I., Cacia, M. A., Signorile, V., Mongiardo, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74407-z · Cited by 17
Jobs, A., Grund, S., de Waha‐Thiele, S., Ledwoch, J., Sievert, H., Rassaf, T., Luedike, P., Kelm, M., Hellhammer, K., Horn, P., et al. (2021) · EuroIntervention · doi:10.4244/eij-d-20-00607 · Cited by 17
Atrial Fibrillation and Transcatheter Repair of Functional Mitral Regurgitation
Kaur, S., Sadana, D., Patel, J., Gad, M. M., Sankaramangalam, K. P., Krishnaswamy, A., Miyasaka, R., Harb, S. C., & Kapadia, S. R. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.06.050 · Cited by 17
Self-citationIliadis, C., Schwabe, L., Müller, D., Stock, S., Baldus, S. E., & Pfister, R. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01789-5 · Cited by 17
Iliadis, C., Spieker, M., Kavsur, R., Metze, C., Hellmich, M., Horn, P., Westenfeld, R., Tiyerili, V., Becher, M. U., Kelm, M., et al. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01804-3 · Cited by 17
Yap, J. J. L., Bolling, S. F., & Rogers, J. H. (2021) · Structural Heart · doi:10.1080/24748706.2021.1895457 · Cited by 17
“In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial, 614 patients with at least moderate-to-severe secondary mitral regurgitation were randomized to transcatheter mitral valve repair with the MitraClip vs optimal…”
MethodTranscatheter Mitral Valve Replacement: Current Evidence and Concepts
Demir, O. M., Bolland, M., Curio, J., Søndergaard, L., Rodés‐Cabau, J., Redwood, S. R., Prendergast, B., Colombo, A., Chau, M. L., & Latib, A. (2021) · Interventional Cardiology Reviews Research Resources · doi:10.15420/icr.2020.25 · Cited by 17
Doldi, P. M., Buech, J., Orban, M., von Samson-Himmelstjerna, P., Wilbert-Lampen, U., Hagl, C. M., Maßberg, S., Näbauer, M., Hausleiter, J., & Braun, D. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.06.031 · Cited by 17
Prendergast, B., & Vahanian, A. S. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab362 · Cited by 17
Advanced heart failure: state of the art and future directions
Masarone, D., Kittleson, M. M., Petraio, A., & Pacileo, G. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2302048 · Cited by 17
Caballero, A., Qin, T., Hahn, R. T., McKay, R. G., & Sun, W. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105855 · Cited by 17
Mitral Interventions in Heart Failure
Lander, M. M., Brener, M. I., Goel, K., Tang, P. C. Y., Verlinden, N. J., ZALAWADIYA, S. K., Lindenfeld, J. M., & Kanwar, M. K. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.07.016 · Cited by 17
Self-citationAssessment and modification of cardiovascular risk in non-cardiac surgery. Clinical guidelines 2023
Sumin, A. N., Duplyakov, D. V., Belyalov, F. I., Баутин, А. Е., Bezdenezhnykh, A. V., Garkina, S. V., Гордеев, М. Л., Zateyshchikov, D. A., Irtyuga, O. B., Korok, E. V., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5555 · Cited by 17
When Pulmonary Hypertension Complicates Heart Failure
Marra, A. M., Benjamin, N., Cittadini, A., Bossone, E., & Grünig, E. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.08.004 · Cited by 17
Weber, M., Öztürk, C., Taramasso, M., Pozzoli, A., Pfister, R., Wösten, M., Alessandrini, H., Latib, A., Denti, P., Kück, K., et al. (2019) · EuroIntervention · doi:10.4244/eij-d-19-00468 · Cited by 17
Atrial functional mitral regurgitation: mechanisms and surgical implications
Fan, Y., Wan, S., Wong, R. H. L., & Lee, A. P. (2020) · Asian Cardiovascular and Thoracic Annals · doi:10.1177/0218492320941388 · Cited by 17
“The rationale of the AHA/ACC guidelines to use 40 mm(2) as a cutoff is based on data from clinical trials that showed percutaneous mitral valve repair improves outcomes (mortality, HF hospitalization, and quality of life) only when ventricular FMR is treated at higher cutoffs of severity.(24) Importantly, the guidelin…”
MethodColor Doppler Splay: A Clue to the Presence of Significant Mitral Regurgitation
Wiener, P. C., Friend, E. J., Bhargav, R., Radhakrishnan, K., Kadem, L., & Pressman, G. S. (2020) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2020.05.002 · Cited by 17
Raheja, H., Ahuja, K. R., Nazir, S., Saad, A. M., Gad, M. M., Chatterjee, S., Abdelfattah, O., Hassanein, M., Harb, S. C., & Kapadia, S. R. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29129 · Cited by 17
Self-citationTabata, N., Weber, M., Sugiura, A., Öztürk, C., Tsujita, K., Nickenig, G., & Sinning, J. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01770-2 · Cited by 17
Patterson, T., Gregson, J., Ērglis, A., Joseph, J. P., Rajani, R., Wilson, K., Prendergast, B., Worthley, S. G., Hildick‐Smith, D., Rafter, T., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2321 · Cited by 17
Transcatheter mitral valve therapies: State of the art
Yousef, S., Arnaoutakis, G. J., Gada, H., Smith, A. J. C., Sanon, S., & Sultan, I. S. (2021) · Journal of Cardiac Surgery · doi:10.1111/jocs.15995 · Cited by 17
Villablanca, P. A., Vemulapalli, S., Stebbins, A., Dai, D., So, C.-Y., Eng, M. H., Wang, D. D., Frisoli, T., Lee, J. C., Kang, G., et al. (2021) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.120.009374 · Cited by 17
Taramasso, M., Gavazzoni, M., & Maisano, F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy722 · Cited by 17
“The recent COAPT and MITRA-FR trials clearly showed that the prognostic benefit of MitraClip is observed in heart failure patients only if the intervention is not performed too late in the course of the disease, and in synergy with optimal medical therapy.(12,13) Similarly, also in isolated FTR, an early indication an…”
MethodLodhi, H., Shaukat, S., Mathews, A. T., Maini, B. S., & Khalili, H. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.09.105 · Cited by 16
Marchetti, D., Lenarda, F. D., Novembre, M. L., Paolisso, P., Schillaci, M., Melotti, E., Doldi, M., Terzi, R., Gallazzi, M., Conte, E., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12227121 · Cited by 16
Ausbuettel, F., Barth, S., Chatzis, G., Sassani, K., Fischer, D., Weyand, S., Mueller, J., Schuett, H., Schieffer, B., Luesebrink, U., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237231 · Cited by 16
“…criteria defined in the Endovascular Valve Edge-to-Edge Repair Study (EVEREST) II for primary MR and in the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) study for secondary MR [12,13].”
MethodHeart Failure and All-Cause Hospitalizations in Patients With Heart Failure: A Meta-Analysis
Sayed, A. A., ElRefaei, M., Awad, K., Salah, H., Mandrola, J. M., & Foy, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.46684 · Cited by 17
Meta-analysis of MitraClip and PASCAL for transcatheter mitral edge-to-edge repair
Balata, M., Gbreel, M. I., Elkasaby, M. H., Hassan, M. N. M., & Becher, M. U. (2025) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-024-03218-4 · Cited by 16
A New Benchmark for Modern Management of Valvular Heart Disease
Wang, Y., Cao, T., Liu, X., He, S., Ran, Z., Du, C., Lu, B., Liu, Y., Shi, J., Liu, L., et al. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.01.017 · Cited by 16
Complementary Transcatheter Therapy for Mitral Regurgitation
Sorajja, P., Bae, R. Y., Gössl, M., Askew, J. A., Jappe, K., Olson, S. H., Schneider, L., & Sun, B. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.12.035 · Cited by 16
“With the large and growing population of patients who may be candidates for such percutaneous approaches, transcatheter devices that are specific for MR and are complementary for both repair and replacement will likely be needed to address unmet clinical needs (2).”
BackgroundBertaina, M., Galluzzo, A., D’Ascenzo, F., Conrotto, F., Marra, W. G., Frea, S., Alunni, G., Crimi, G., Moretti, C., Montefusco, A., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.05.015 · Cited by 16
Self-citation
Metadata
- Authors
- Stone, G. W., Lindenfeld, J., Abraham, W. T., Kar, S., Lim, D. S., Mishell, J. M., Whisenant, B., Grayburn, P. A., Rinaldi, M., Kapadia, S. R., Rajagopal, V., Sarembock, I. J., Brieke, A., Marx, S. O., Cohen, D. J., Weissman, N. J., & Mack, M. J.
- Affiliations
- NewYork–Presbyterian Hospital (US)
- Cedars-Sinai Medical Center (US)
- Cleveland Clinic (US)
- University of Colorado Hospital (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-12-13
- Volume
- 379
- Issue
- 24
- Pages
- 2307-2318
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2889688444
- Cited by
- 3,017
- References
- 23
- Citations by year
- 2026: 253 · 2025: 330 · 2024: 308 · 2023: 372 · 2022: 385 · 2021: 486 · 2020: 453 · 2019: 376 · 2018: 42
- FWCI
- 256.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Surgery › Cardiac Structural Anomalies and Repair
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Keywords
- transcatheter mitral valve repair, heart failure, functional mitral regurgitation, left ventricular dysfunction, heart failure hospitalization, all-cause mortality, device complications, guideline-directed medical therapy, COAPT trial, transcatheter edge-to-edge repair, mitral valve repair, transcatheter closure devices, transcatheter aortic valve implantation, transcatheter mitral valve replacement
- MeSH terms
- Aged, Aged, 80 and over, Combined Modality Therapy, Female, Heart Failure, Heart Valve Prosthesis, Hospitalization, Humans, Male, Middle Aged, Mitral Valve, Mitral Valve Insufficiency, Prosthesis Failure, Stroke Volume, Treatment Outcome, Ventricular Dysfunction, Left, Heart Valve Prosthesis Implantation, Kaplan-Meier Estimate, Intention to Treat Analysis, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.